Scribe Therapeutics IPO: $13–$15 price range set for $100M offering
As seen on the 24/7 Wall St. homepage on July 20, 2026.
Scribe Therapeutics amended S-1 filing locks in IPO pricing band
CRISPR biotech Scribe Therapeutics set a $13-$15 price range for its $100 million IPO, signaling confidence as gene-editing investments regain momentum after years of sector skepticism.
Continue ReadingShow less
Scribe Therapeutics is offering 7,150,000 shares in its Nasdaq debut under the proposed ticker SCTX, with the $13–$15 price band implying a deal size of roughly $100 million at the midpoint. The amended S-1 filing, submitted July 20, 2026, formalizes the pricing range and marks a significant step toward the company's public market entry.
The CRISPR gene-editing space has faced prolonged skepticism from investors, making a nine-figure IPO at this price range a notable signal of renewed appetite for the sector. Scribe's willingness to set a defined band rather than delay or withdraw suggests its underwriters see sufficient institutional demand to support the offering.
Sponsored
Free Report, Just Released
The Top 10 Stocks To Buy Now
24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.
The report is free, and you can see why we think each stock is a top investment today.
With a final price not yet set, the deal remains in motion. Investors watching the gene-editing space will want to track where Scribe ultimately prices relative to the $13–$15 range, as a price above or below that band will speak directly to how the market is weighing the current momentum in CRISPR therapeutics.
Mentioned: SCTX